Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A hoosier oncology group trial, HEM01-21

Attaya Suvannasankha, Christopher Fausel, Beth E. Juliar, Constantin Yiannoutsos, William B. Fisher, Rafat H. Ansari, Lisa L. Wood, Gina G. Smith, Larry Cripe, Rafat Abonour

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Thalidomide has direct antimyeloma and immunomodulatory effects. In addition, both thalidomide and metronomic chemotherapy inhibit angiogenesis. The synergy of such a combination may decrease toxicity while maintaining efficacy. The Hoosier Oncology Group conducted a phase II trial of oral cyclophosphamide (50 mg b.i.d. for 21 days), thalidomide (200 mg/day), and prednisone (50 mg q.o.d.) (CTP) per 28-day course in patients with relapsed multiple myeloma (MM). Of the 37 patients enrolled, 16 had prior stem cell transplantation. The median follow-up time was 25.3 months (95% confidence interval [CI] 23.2-27.7). Of 35 patients treated, 22 patients (62.9%) responded: 7 (20.0%) complete responses, 2 (5.7%) near-complete responses, and 13 (37.1%) partial responses. Eight patients (22.9%) had stable disease, and three (8.6%) had disease progression. Two patients withdrew from the study early due to reasons unrelated to progression or toxicity and were treated as nonresponders. The median time to best response and time to progression were 3.6 months (95% CI 2.8-10.9) and 13.2 months (95% CI 9.4-21.0), respectively. The median number of treatment cycles was seven (range 1-12 cycles). Grade III to IV toxicities included leukopenia (42.9%; febrile neutropenia, 11.4%), hyperglycemia (20%), sensory neuropathy (11.4%), thromboses (8%), and motor neuropathy (5.7%). No patient withdrew from the study due to toxicity. The efficacy and low toxicity of the CTP regimen support the future development of such an approach in MM.

Original languageEnglish
Pages (from-to)99-106
Number of pages8
JournalOncologist
Volume12
Issue number1
DOIs
StatePublished - 2007

Fingerprint

Thalidomide
Prednisone
Multiple Myeloma
Cyclophosphamide
Cytidine Triphosphate
Confidence Intervals
Febrile Neutropenia
Leukopenia
Stem Cell Transplantation
Hyperglycemia
Reaction Time
Disease Progression
Thrombosis
Drug Therapy

Keywords

  • Antineoplastic-combined chemotherapy protocols
  • Cyclophosphamide
  • Dexamethasone
  • Multiple myeloma
  • Oral administration
  • Salvage therapy
  • Thalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma : A hoosier oncology group trial, HEM01-21. / Suvannasankha, Attaya; Fausel, Christopher; Juliar, Beth E.; Yiannoutsos, Constantin; Fisher, William B.; Ansari, Rafat H.; Wood, Lisa L.; Smith, Gina G.; Cripe, Larry; Abonour, Rafat.

In: Oncologist, Vol. 12, No. 1, 2007, p. 99-106.

Research output: Contribution to journalArticle

@article{a310ef69bed5482fb0444858a576da56,
title = "Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A hoosier oncology group trial, HEM01-21",
abstract = "Thalidomide has direct antimyeloma and immunomodulatory effects. In addition, both thalidomide and metronomic chemotherapy inhibit angiogenesis. The synergy of such a combination may decrease toxicity while maintaining efficacy. The Hoosier Oncology Group conducted a phase II trial of oral cyclophosphamide (50 mg b.i.d. for 21 days), thalidomide (200 mg/day), and prednisone (50 mg q.o.d.) (CTP) per 28-day course in patients with relapsed multiple myeloma (MM). Of the 37 patients enrolled, 16 had prior stem cell transplantation. The median follow-up time was 25.3 months (95{\%} confidence interval [CI] 23.2-27.7). Of 35 patients treated, 22 patients (62.9{\%}) responded: 7 (20.0{\%}) complete responses, 2 (5.7{\%}) near-complete responses, and 13 (37.1{\%}) partial responses. Eight patients (22.9{\%}) had stable disease, and three (8.6{\%}) had disease progression. Two patients withdrew from the study early due to reasons unrelated to progression or toxicity and were treated as nonresponders. The median time to best response and time to progression were 3.6 months (95{\%} CI 2.8-10.9) and 13.2 months (95{\%} CI 9.4-21.0), respectively. The median number of treatment cycles was seven (range 1-12 cycles). Grade III to IV toxicities included leukopenia (42.9{\%}; febrile neutropenia, 11.4{\%}), hyperglycemia (20{\%}), sensory neuropathy (11.4{\%}), thromboses (8{\%}), and motor neuropathy (5.7{\%}). No patient withdrew from the study due to toxicity. The efficacy and low toxicity of the CTP regimen support the future development of such an approach in MM.",
keywords = "Antineoplastic-combined chemotherapy protocols, Cyclophosphamide, Dexamethasone, Multiple myeloma, Oral administration, Salvage therapy, Thalidomide",
author = "Attaya Suvannasankha and Christopher Fausel and Juliar, {Beth E.} and Constantin Yiannoutsos and Fisher, {William B.} and Ansari, {Rafat H.} and Wood, {Lisa L.} and Smith, {Gina G.} and Larry Cripe and Rafat Abonour",
year = "2007",
doi = "10.1634/theoncologist.12-1-99",
language = "English",
volume = "12",
pages = "99--106",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma

T2 - A hoosier oncology group trial, HEM01-21

AU - Suvannasankha, Attaya

AU - Fausel, Christopher

AU - Juliar, Beth E.

AU - Yiannoutsos, Constantin

AU - Fisher, William B.

AU - Ansari, Rafat H.

AU - Wood, Lisa L.

AU - Smith, Gina G.

AU - Cripe, Larry

AU - Abonour, Rafat

PY - 2007

Y1 - 2007

N2 - Thalidomide has direct antimyeloma and immunomodulatory effects. In addition, both thalidomide and metronomic chemotherapy inhibit angiogenesis. The synergy of such a combination may decrease toxicity while maintaining efficacy. The Hoosier Oncology Group conducted a phase II trial of oral cyclophosphamide (50 mg b.i.d. for 21 days), thalidomide (200 mg/day), and prednisone (50 mg q.o.d.) (CTP) per 28-day course in patients with relapsed multiple myeloma (MM). Of the 37 patients enrolled, 16 had prior stem cell transplantation. The median follow-up time was 25.3 months (95% confidence interval [CI] 23.2-27.7). Of 35 patients treated, 22 patients (62.9%) responded: 7 (20.0%) complete responses, 2 (5.7%) near-complete responses, and 13 (37.1%) partial responses. Eight patients (22.9%) had stable disease, and three (8.6%) had disease progression. Two patients withdrew from the study early due to reasons unrelated to progression or toxicity and were treated as nonresponders. The median time to best response and time to progression were 3.6 months (95% CI 2.8-10.9) and 13.2 months (95% CI 9.4-21.0), respectively. The median number of treatment cycles was seven (range 1-12 cycles). Grade III to IV toxicities included leukopenia (42.9%; febrile neutropenia, 11.4%), hyperglycemia (20%), sensory neuropathy (11.4%), thromboses (8%), and motor neuropathy (5.7%). No patient withdrew from the study due to toxicity. The efficacy and low toxicity of the CTP regimen support the future development of such an approach in MM.

AB - Thalidomide has direct antimyeloma and immunomodulatory effects. In addition, both thalidomide and metronomic chemotherapy inhibit angiogenesis. The synergy of such a combination may decrease toxicity while maintaining efficacy. The Hoosier Oncology Group conducted a phase II trial of oral cyclophosphamide (50 mg b.i.d. for 21 days), thalidomide (200 mg/day), and prednisone (50 mg q.o.d.) (CTP) per 28-day course in patients with relapsed multiple myeloma (MM). Of the 37 patients enrolled, 16 had prior stem cell transplantation. The median follow-up time was 25.3 months (95% confidence interval [CI] 23.2-27.7). Of 35 patients treated, 22 patients (62.9%) responded: 7 (20.0%) complete responses, 2 (5.7%) near-complete responses, and 13 (37.1%) partial responses. Eight patients (22.9%) had stable disease, and three (8.6%) had disease progression. Two patients withdrew from the study early due to reasons unrelated to progression or toxicity and were treated as nonresponders. The median time to best response and time to progression were 3.6 months (95% CI 2.8-10.9) and 13.2 months (95% CI 9.4-21.0), respectively. The median number of treatment cycles was seven (range 1-12 cycles). Grade III to IV toxicities included leukopenia (42.9%; febrile neutropenia, 11.4%), hyperglycemia (20%), sensory neuropathy (11.4%), thromboses (8%), and motor neuropathy (5.7%). No patient withdrew from the study due to toxicity. The efficacy and low toxicity of the CTP regimen support the future development of such an approach in MM.

KW - Antineoplastic-combined chemotherapy protocols

KW - Cyclophosphamide

KW - Dexamethasone

KW - Multiple myeloma

KW - Oral administration

KW - Salvage therapy

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=33846447117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846447117&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.12-1-99

DO - 10.1634/theoncologist.12-1-99

M3 - Article

C2 - 17227904

AN - SCOPUS:33846447117

VL - 12

SP - 99

EP - 106

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 1

ER -